Driessen, Julia http://orcid.org/0000-0001-9364-2501
Kersten, Marie José http://orcid.org/0000-0002-8904-3802
Visser, Lydia
van den Berg, Anke http://orcid.org/0000-0002-8894-2638
Tonino, Sanne H.
Zijlstra, Josée M.
Lugtenburg, Pieternella J.
Morschhauser, Franck http://orcid.org/0000-0002-3714-9824
Hutchings, Martin
Amorim, Sandy
Gastinne, Thomas
Nijland, Marcel
Zwezerijnen, Gerben J. C.
Boellaard, Ronald
de Vet, Henrica C. W.
Arens, Anne I. J. http://orcid.org/0000-0001-7066-5372
Valkema, Roelf
Liu, Roberto D. K.
Drees, Esther E. E. http://orcid.org/0000-0003-3551-0038
de Jong, Daphne
Plattel, Wouter J.
Diepstra, Arjan http://orcid.org/0000-0001-9239-1050
,
Article History
Received: 17 February 2022
Revised: 20 August 2022
Accepted: 26 September 2022
First Online: 14 October 2022
Competing interests
: The study drug (BV) was provided for the study and the study was funded by Takeda. Takeda did not have any influence on the data analysis or the interpretation of the results. MJK: honoraria from and consulting/advisory role for BMS/Celgene, Kite, a Gilead Company, Miltenyi Biotech, Novartis, Adicet Bio and Roche; research funding from Kite, a Gilead Company, and Takeda; and travel support from Kite, A Gilead Company, Miltenyi Biotech, Novartis, and Roche. MH: Consultant/advisor: Roche, Takeda, Celgene, Genmab; Research support: Roche, Takeda, Celgene, Genmab, Novartis, Janssen, Incyte, Genentech. PJL: honoraria from and consulting/advisory role for Takeda, Servier, Roche, Genmab, AbbVie, Incyte, Regeneron, Celgene; Research funding from Takeda, Servier and Roche. FM: advisory boards for Roche, BMS, Genmab, Abbvie, Miltenyi, Novartis, Gilead, Asrtra Zeneca. Scientific lectures for Roche, Janssen. Consultancy for Roche, Genmab, Abbvie, Gilead. AD: Millennium/Takeda: Consultancy, Honoraria, Research Funding. TG: Millennium/Takeda: Honoraria, Gilead, Roche, MSD. JMZ: Consultant/advisor: Gilead, Roche, Takeda; Honoraria: Gilead, Roche, Takeda, Janssen. DdJ: Consultant/advisor: Takeda. SHT: Consultant/advisor: Takeda, Kite/Gilead; Research Funding: Beigene. The other authors declare no potential conflicts of interest.